Savara Inc. SVRA
4.26 USD -0.95 (-18.23%)
Regular-session close
4.30 +0.04 +0.94%
After hours · Nov 20, 7:55 PM ET
4.00 Day range 4.52
4.00 52-week range 7.01
- YTD
- -29.35%
- 1 year
- -8.78%
5D -0.35 (-7.42%)
- Market cap
- 939.86M
- EPS (ttm)
- -0.60
- Shares out
- 220.62M
- Forward P/E
- -14.09
- YTD return
- -29.35%
- 1-year return
- -8.78%
- 50-day average
- 4.88
- 200-day average
- 5.32
- Enterprise value
- 1.17B
- Price / book
- 12.29
- Volume
- 17.08M
- Avg volume
- 2.57M
- Open
- 4.18
- Previous close
- 5.21
- Day's range
- 4.00 – 4.52
- 52-week range
- 4.00 – 7.01
- Beta
- 0.30
- Analysts
- Strong Buy
- Price target
- 11.06 (+159.5%)
- Earnings date
- Mar 12, 2027
Key statistics
- Free cash flow
- -73.67M
- Total cash
- 131.31M
- Total debt
- 31.57M
- Return on equity
- -151.05%
- Short % of float
- 18.35%
Fundamental scorecard
3 of 25 checks passed on SVRA’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 11.06 +159.5% upside
Now 4.26
- Target (low)
- 9.00
- Target (mean)
- 11.06
- Target (high)
- 16.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy3
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 12, 2027
Expected Mar 12, 2027. Consensus EPS estimate -0.16898.
Financials — quick view
SVRA Revenue — quarterly 0
SVRA Net income — quarterly -42.99M
SVRA EPS — quarterly -0.17
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 12, 2027 | Dec 30, 2026 | -0.18 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.17556 | -0.17 | +0.01 | +3.17% |
| Aug 11, 2026 | Jun 30, 2026 | -0.14125 | -0.16 | -0.02 | -13.27% |
| May 12, 2026 | Mar 31, 2026 | -0.14 | -0.15 | -0.01 | -7.14% |
| Mar 13, 2026 | Dec 31, 2025 | -0.12 | -0.13 | -0.01 | -8.33% |
| Nov 12, 2025 | Sep 30, 2025 | -0.13 | -0.14 | -0.01 | -7.69% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | JP Morgan | init | — | Overweight |
| Dec 23, 2025 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 18, 2025 | Wells Fargo | main | Overweight | Overweight |
| Nov 14, 2025 | Oppenheimer | main | Outperform | Outperform |
| Nov 13, 2025 | Citizens | main | Market Outperform | Market Outperform |
| Oct 23, 2025 | JMP Securities | main | Market Outperform | Market Outperform |
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- savarapharma.com
News
HC Wainwright & Co. Maintains Buy on Savara, Lowers Price Target to $9
Gold Falls Sharply; US Consumer Sentiment Rises In November
Savara Craters as FDA Delays Decision for Lung Disease Savara Says FDA Will Not Meet PDUFA Target Action Date Of November 22 For Molgramostim Inhalation Solution BLA For Treatment Of Autoimmune PAP; No Revised Action Date Communicated By The FDA
Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date
Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
Savara: The Market May Be Overestimating Its FDA Risk HC Wainwright & Co. Assumes Savara at Buy, Announces Price Target of $10
Savara Presents Clinical Trial Post-Hoc Analysis Of IMPALA At CHEST 2026 Annual Meeting To Evaluate Effects Of Molgramostim In aPAP Patients
Your note
Sign in to keep a note on SVRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ELAM NEVAN C | Director | Stock Award(Grant) | Dec 8, 2025 | 106,887 |
| ERICKSON ANNE | Officer | Stock Award(Grant) | Dec 11, 2024 | 434,672 |
| HAWKINS RICHARD JAMES | Director | Stock Award(Grant) | Dec 8, 2025 | 161,326 |
| LOWRANCE DAVID L. CPA | Chief Financial Officer | Sale | Jun 21, 2026 | 536,032 |
| LUTZ ROBERT MATTHEW | Chief Operating Officer | Stock Award(Grant) | Jul 14, 2026 | 328,977 |
| MCCRACKEN JOSEPH S | Director | Conversion of Exercise of derivative security | Feb 12, 2026 | 302,644 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 11.09% | 24,471,264 | 127.50M | Sep 29, 2026 |
| Venrock Adviser, LLC | 8.87% | 19,568,534 | 101.95M | Sep 29, 2026 |
| Bain Capital Life Sciences Investors, LLC | 7.98% | 17,600,621 | 91.70M | Sep 29, 2026 |
| Deerfield Management Company, L.P | 6.15% | 13,569,000 | 70.69M | Sep 29, 2026 |
| Blackrock Inc. | 5.71% | 12,588,886 | 65.59M | Sep 29, 2026 |
| TCG Crossover Management, LLC | 5.60% | 12,362,205 | 64.41M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.79% | 6,164,961 | 32.12M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.80% | 3,969,421 | 20.68M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.44% | 3,183,757 | 16.59M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.76% | 1,677,986 | 8.74M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.71% | 1,555,905 | 8.11M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.64% | 1,421,946 | 7.41M | Sep 29, 2026 |
